This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
HIV/AIDS	HIV capsid protein	<p><i>In vitro</i> studies identified HIV capsid protein inhibitors that could help treat HIV. In antiviral assays of peripheral blood mononuclear cells (PBMCs), compounds that bound a pocket in the N-terminal domain of the HIV capsid protein inhibited entry of HIV-1 and HIV-2 strains and HIV-1 clinical isolates compared with no treatment. Next steps include testing the inhibitors in animal models of HIV infection.</p> <p>Myrex Inc. has the oral HIV capsid protein inhibitor bevirimat dimeglumine in Phase II testing for the indication.</p> <p>Panacos Pharmaceuticals Inc. has the tablet form of bevirimat in Phase II testing to treat HIV.</p> <p>SciBX 4(3); doi:10.1038/scibx.2011.74 Published online Jan. 20, 2011</p>	Patent and licensing status unavailable	<p>Blair, W.S. <i>et al.</i> <i>PLoS Pathog.</i>; published online Dec. 9, 2010; doi:10.1371/journal.ppat.1001220</p> <p>Contact: Scott L. Butler, Pfizer Global Research and Development, Sandwich, U.K. e-mail: scott.butler@pfizer.com</p>